Prevention and Treatment of Tumor Lysis Syndrome in the Era of Onco-Nephrology Progress

Background: Tumor lysis syndrome (TLS) is an oncologic emergency due to a rapid break down of malignant cells usually induced by cytotoxic therapy, with hyperuricemia, hyperkalemia, hyperphosphatemia, hypocalcemia, and serious clinical consequences such as acute renal injury, cardiac arrhythmia, hyp...

Full description

Bibliographic Details
Main Authors: Joanna Matuszkiewicz-Rowinska, Jolanta Malyszko
Format: Article
Language:English
Published: Karger Publishers 2020-09-01
Series:Kidney & Blood Pressure Research
Subjects:
Online Access:https://www.karger.com/Article/FullText/509934
id doaj-bd594d2400d246a5a08beba761eb8e72
record_format Article
spelling doaj-bd594d2400d246a5a08beba761eb8e722020-11-25T04:07:59ZengKarger PublishersKidney & Blood Pressure Research1420-40961423-01432020-09-0145564566010.1159/000509934509934Prevention and Treatment of Tumor Lysis Syndrome in the Era of Onco-Nephrology ProgressJoanna Matuszkiewicz-RowinskaJolanta MalyszkoBackground: Tumor lysis syndrome (TLS) is an oncologic emergency due to a rapid break down of malignant cells usually induced by cytotoxic therapy, with hyperuricemia, hyperkalemia, hyperphosphatemia, hypocalcemia, and serious clinical consequences such as acute renal injury, cardiac arrhythmia, hypotension, and death. Rapidly expanding knowledge of cancer immune evasion mechanisms and host-tumor interactions has significantly changed our therapeutic strategies in hemato-oncology what resulted in the expanding spectrum of neoplasms with a risk of TLS. Summary: Since clinical TLS is a life-threatening condition, identifying patients with risk factors for TLS development and implementation of adequate preventive measures remains the most critical component of its medical management. In general, these consist of vigilant laboratory and clinical monitoring, vigorous IV hydration, urate-lowering therapy, avoidance of exogenous potassium, use of phosphate binders, and – in high-risk cases – considering cytoreduction before the start of the aggressive agent or a gradual escalation of its dose. Key Messages: In patients with a high risk of TLS, cytotoxic chemotherapy should be given in the facility with ready access to dialysis and a treatment plan discussed with the nephrology team. In the case of hyperkalemia, severe hyperphosphatemia or acidosis, and fluid overload unresponsive to diuretic therapy, the early renal replacement therapy (RRT) should be considered. One must remember that in TLS, the threshold for RRT initiation may be lower than in other clinical situations since the process of cell breakdown is ongoing, and rapid increases in serum electrolytes cannot be predicted.https://www.karger.com/Article/FullText/509934tumor lysis syndromeacute kidney injuryhyperuricemiahyperphosphatemiaallopurinolrasburicase
collection DOAJ
language English
format Article
sources DOAJ
author Joanna Matuszkiewicz-Rowinska
Jolanta Malyszko
spellingShingle Joanna Matuszkiewicz-Rowinska
Jolanta Malyszko
Prevention and Treatment of Tumor Lysis Syndrome in the Era of Onco-Nephrology Progress
Kidney & Blood Pressure Research
tumor lysis syndrome
acute kidney injury
hyperuricemia
hyperphosphatemia
allopurinol
rasburicase
author_facet Joanna Matuszkiewicz-Rowinska
Jolanta Malyszko
author_sort Joanna Matuszkiewicz-Rowinska
title Prevention and Treatment of Tumor Lysis Syndrome in the Era of Onco-Nephrology Progress
title_short Prevention and Treatment of Tumor Lysis Syndrome in the Era of Onco-Nephrology Progress
title_full Prevention and Treatment of Tumor Lysis Syndrome in the Era of Onco-Nephrology Progress
title_fullStr Prevention and Treatment of Tumor Lysis Syndrome in the Era of Onco-Nephrology Progress
title_full_unstemmed Prevention and Treatment of Tumor Lysis Syndrome in the Era of Onco-Nephrology Progress
title_sort prevention and treatment of tumor lysis syndrome in the era of onco-nephrology progress
publisher Karger Publishers
series Kidney & Blood Pressure Research
issn 1420-4096
1423-0143
publishDate 2020-09-01
description Background: Tumor lysis syndrome (TLS) is an oncologic emergency due to a rapid break down of malignant cells usually induced by cytotoxic therapy, with hyperuricemia, hyperkalemia, hyperphosphatemia, hypocalcemia, and serious clinical consequences such as acute renal injury, cardiac arrhythmia, hypotension, and death. Rapidly expanding knowledge of cancer immune evasion mechanisms and host-tumor interactions has significantly changed our therapeutic strategies in hemato-oncology what resulted in the expanding spectrum of neoplasms with a risk of TLS. Summary: Since clinical TLS is a life-threatening condition, identifying patients with risk factors for TLS development and implementation of adequate preventive measures remains the most critical component of its medical management. In general, these consist of vigilant laboratory and clinical monitoring, vigorous IV hydration, urate-lowering therapy, avoidance of exogenous potassium, use of phosphate binders, and – in high-risk cases – considering cytoreduction before the start of the aggressive agent or a gradual escalation of its dose. Key Messages: In patients with a high risk of TLS, cytotoxic chemotherapy should be given in the facility with ready access to dialysis and a treatment plan discussed with the nephrology team. In the case of hyperkalemia, severe hyperphosphatemia or acidosis, and fluid overload unresponsive to diuretic therapy, the early renal replacement therapy (RRT) should be considered. One must remember that in TLS, the threshold for RRT initiation may be lower than in other clinical situations since the process of cell breakdown is ongoing, and rapid increases in serum electrolytes cannot be predicted.
topic tumor lysis syndrome
acute kidney injury
hyperuricemia
hyperphosphatemia
allopurinol
rasburicase
url https://www.karger.com/Article/FullText/509934
work_keys_str_mv AT joannamatuszkiewiczrowinska preventionandtreatmentoftumorlysissyndromeintheeraofonconephrologyprogress
AT jolantamalyszko preventionandtreatmentoftumorlysissyndromeintheeraofonconephrologyprogress
_version_ 1724427178877124608